AbCellera Biologics (ABCL) to Release Quarterly Earnings on Tuesday

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) is anticipated to post its quarterly earnings results after the market closes on Tuesday, February 18th. Analysts expect AbCellera Biologics to post earnings of ($0.15) per share for the quarter. Individual interested in listening to the company's earnings conference call can do so using this link.

AbCellera Biologics Trading Up 4.1 %

ABCL stock traded up $0.13 during midday trading on Friday, hitting $3.27. The company had a trading volume of 5,957,272 shares, compared to its average volume of 3,871,791. AbCellera Biologics has a 52 week low of $2.34 and a 52 week high of $5.45. The stock's 50 day moving average price is $3.06 and its 200 day moving average price is $2.83. The stock has a market cap of $965.86 million, a price-to-earnings ratio of -5.36 and a beta of 0.42.

Analyst Ratings Changes

Several analysts have weighed in on the company. Benchmark reiterated a "hold" rating on shares of AbCellera Biologics in a research report on Tuesday, November 5th. KeyCorp reduced their price target on AbCellera Biologics from $5.00 to $4.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 8th. Finally, Stifel Nicolaus reaffirmed a "buy" rating and issued a $12.00 price target (down from $14.00) on shares of AbCellera Biologics in a research note on Tuesday, November 5th.

AbCellera Biologics Company Profile

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.